Biotech RadarJobs updated

COMPANY

Dragonfly Therapeutics

HQ: Waltham, MA source · dragonflytx.com ↗

Clinical Phase 2

Keywords: oncology immunology autoimmune disease fibrosis Solid Tumor Cancer DF5112 DF1001 DF6215 DF6002 DF9001

Location: Waltham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults source ↗
  2. Trial start Phase 1: Study of DF6215 in Patients With Advanced Solid Tumors source ↗
  3. Trial start Phase 1/Phase 2: Study of DF9001 in Patients With Advanced Solid Tumors source ↗
  4. Trial start Phase 1: A Study of DF6002 Alone and in Combination With Nivolumab source ↗
  5. Trial start Phase 1/Phase 2: Study of DF1001 in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07232121A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy AdultsPhase 1RecruitingJan 12, 20262026-12 (estimated)
NCT04143711Study of DF1001 in Patients With Advanced Solid TumorsPhase 1/Phase 2CompletedNov 11, 2019Dec 5, 2025 (actual)
NCT06108479Study of DF6215 in Patients With Advanced Solid TumorsPhase 1CompletedNov 28, 2023Dec 4, 2025 (actual)
NCT04423029A Study of DF6002 Alone and in Combination With NivolumabPhase 1CompletedJul 13, 2020Nov 26, 2025 (actual)
NCT05597839Study of DF9001 in Patients With Advanced Solid TumorsPhase 1/Phase 2CompletedNov 15, 2022Aug 15, 2025 (actual)
Feedback